Evidence map›Paper›PMID 33206936›Full record

Trial reportBlood2021

Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia.

Jenny Klintman, Niamh Appleby, Basile Stamatopoulos, Katie Ridout, Toby A Eyre, Pauline Robbe, Laura Lopez Pascua, Samantha J L Knight, Helene Dreau, Maite Cabes and 9 more

Registry-linked trialOpen access · bronzeAbstract readClinical Trial, Phase IIComparative StudyMulticenter Study
In one paragraph

Trial report in Blood, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03899337 (A Phase II, Randomised Study of CHOP-R in Combination With Acalabrutinib Compared to CHOP-R in Patients With Newly Diagnosed Richter's Syndrome and a Platform for Initial Investigations Into Activity of Novel Treatments in Relapsed/Refractory and Newly Diagnosed Richter's Syndrome.), which is not on this map. Cited by 61 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 1 pooled it
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03899337 phase2active not recruitingnot on this map

A Phase II, Randomised Study of CHOP-R in Combination With Acalabrutinib Compared to CHOP-R in Patients With Newly Diagnosed Richter's Syndrome and a Platform for Initial Investigations Into Activity of Novel Treatments in Relapsed/Refractory and Newly Diagnosed Richter's Syndrome.

TypeinterventionalSponsorUniversity of BirminghamRan2019 to 2028Enrolled72ConditionsRichter SyndromeArmsAcalabrutinib, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone
3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 1 synthesis or guideline pooled it, 85 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Science translational medicine · 2024
    Article
  18. Review
  19. Review
  20. Article

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 9 institutions in 5 countries.

Jenny KlintmanMolecular Diagnostic Centre, Department of Oncology, University of Oxford, Oxford, United Kingdom.
Niamh ApplebyMolecular Diagnostic Centre, Department of Oncology, University of Oxford, Oxford, United Kingdom.ORCID 0000-0001-5063-9652
Basile StamatopoulosMolecular Diagnostic Centre, Department of Oncology, University of Oxford, Oxford, United Kingdom.
Katie RidoutMolecular Diagnostic Centre, Department of Oncology, University of Oxford, Oxford, United Kingdom.
Toby A EyreDepartment of Hematology, Oxford University Hospitals National Health Service (NHS) Trust, Oxford, United Kingdom.ORCID 0000-0002-6631-9749
Pauline RobbeMolecular Diagnostic Centre, Department of Oncology, University of Oxford, Oxford, United Kingdom.ORCID 0000-0002-0691-1126
Laura Lopez PascuaMolecular Diagnostic Centre, Department of Oncology, University of Oxford, Oxford, United Kingdom.
Samantha J L KnightNational Institute for Health Research (NIHR) Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom.
Helene DreauMolecular Diagnostic Centre, Department of Oncology, University of Oxford, Oxford, United Kingdom.
Maite CabesDepartment of Hematology, Oxford University Hospitals National Health Service (NHS) Trust, Oxford, United Kingdom.
Niko PopitschNational Institute for Health Research (NIHR) Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom.
Mats EhingerPathology, Department of Clinical Sciences, Skåne University Hospital, Lund University, Lund, Sweden.
Jose I Martín-SuberoInstitut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Barcelona, Spain.
Elías CampoInstitut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Barcelona, Spain.ORCID 0000-0001-9850-9793
Robert MånssonCenter for Hematology and Regenerative Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0003-0738-0328
Davide RossiInstitute of Oncology Research (IOR), Bellinzona, Switzerland.
Jenny C TaylorNational Institute for Health Research (NIHR) Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom.
Dimitrios V VavoulisMolecular Diagnostic Centre, Department of Oncology, University of Oxford, Oxford, United Kingdom.ORCID 0000-0002-3984-1507
Anna SchuhMolecular Diagnostic Centre, Department of Oncology, University of Oxford, Oxford, United Kingdom.ORCID 0000-0002-3938-8490
Centre for Human Genetics · GBNational Health Service · GBUniversity of Oxford · GBLund University · SEConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESInstitució Catalana de Recerca i Estudis Avançats · ESInstitute of Oncology Research · CHKarolinska University Hospital · SEUniversité Libre de Bruxelles · BE

Funding

Wellcome Trust 203141/Z/16/Z
6 · The paper itself

Abstract

The transformation of chronic lymphocytic leukemia (CLL) to high-grade B-cell lymphoma is known as Richter syndrome (RS), a rare event with dismal prognosis. In this study, we conducted whole-genome sequencing (WGS) of paired circulating CLL (PB-CLL) and RS biopsies (tissue-RS) from 17 patients recruited into a clinical trial (CHOP-O). We found that tissue-RS was enriched for mutations in poor-risk CLL drivers and genes in the DNA damage response (DDR) pathway. In addition, we identified genomic aberrations not previously implicated in RS, including the protein tyrosine phosphatase receptor (PTPRD) and tumor necrosis factor receptor-associated factor 3 (TRAF3). In the noncoding genome, we discovered activation-induced cytidine deaminase-related and unrelated kataegis in tissue-RS affecting regulatory regions of key immune-regulatory genes. These include BTG2, CXCR4, NFATC1, PAX5, NOTCH-1, SLC44A5, FCRL3, SELL, TNIP2, and TRIM13. Furthermore, differences between the global mutation signatures of pairs of PB-CLL and tissue-RS samples implicate DDR as the dominant mechanism driving transformation. Pathway-based clonal deconvolution analysis showed that genes in the MAPK and DDR pathways demonstrate high clonal-expansion probability. Direct comparison of nodal-CLL and tissue-RS pairs from an independent cohort confirmed differential expression of the same pathways by RNA expression profiling. Our integrated analysis of WGS and RNA expression data significantly extends previous targeted approaches, which were limited by the lack of germline samples, and it facilitates the identification of novel genomic correlates implicated in RS transformation, which could be targeted therapeutically. Our results inform the future selection of investigative agents for a UK clinical platform study. This trial was registered at www.clinicaltrials.gov as #NCT03899337.

Indexed as

TranscriptomeAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBase SequenceClonal EvolutionClone CellsCombined Modality TherapyCyclophosphamideDisease ProgressionDNA RepairDoxorubicinFemaleGene Expression Regulation, NeoplasticGene Regulatory NetworksAntibodies, Monoclonal, HumanizedCyclophosphamideDoxorubicinNeoplasm ProteinsofatumumabPrednisoneRNA, NeoplasmVincristine

Identifiers

PMID33206936
PMCPMC8163497
OpenAlexW3106137033

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.